Back to top
more

Adicet Bio (ACET)

(Delayed Data from NSDQ)

$1.05 USD

1.05
947,144

-0.09 (-7.89%)

Updated Nov 14, 2024 04:00 PM ET

After-Market: $1.06 +0.01 (0.95%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Acadia (ACAD) Q3 Earnings and Sales Beat Estimates, Stock Up

by Zacks Equity Research

Acadia (ACAD) reports better-than-expected third-quarter 2023 results as both earnings and sales beat estimates. The stock rises in after-market hours.

Pacira (PCRX) Q3 Earnings and Revenues Miss, '23 View Updated

by Zacks Equity Research

Pacira (PCRX) announces weaker-than-expected third-quarter 2023 results. The company streamlines its 2023 guidance for net Exparel sales.

Novo Nordisk (NVO) Q3 Earnings and Sales Beat, 2023 View Up

by Zacks Equity Research

Novo Nordisk (NVO) reports encouraging third-quarter results, beating both earnings and sales estimates, driven by strong sales of diabetes and obesity care products. Management raises 2023 guidance.

Deciphera (DCPH) Stock Gains 17% on Q3 Earnings & Sales Beat

by Zacks Equity Research

Deciphera (DCPH) reports better-than-expected third-quarter 2023 results, wherein earnings and revenues beat estimates, driven by increased Qinlock sales. The stock rises 17%.

Dr. Reddy's (RDY) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Dr. Reddy's (RDY) reports better-than-expected fiscal second-quarter 2024 results where both earnings and revenues beat estimates, driven by growth in core businesses in North America and Europe.

Blueprint (BPMC) Stock Gains 26% on Q3 Earnings & Sales Beat

by Zacks Equity Research

Blueprint (BPMC) climbs 26% on better-than-expected third-quarter 2023 results, driven by increased Ayvakit sales following the drug's label expansion in the United States.

Bristol Myers' (BMY) Opdivo SC Meets Kidney Cancer Study Goals

by Zacks Equity Research

Bristol Myers' (BMY) subcutaneous formulation of Opdivo, developed using Halozyme's Enhanze technology, meets noninferiority goals in a late-stage kidney cancer study compared with intravenous Opdivo.

Ardelyx (ARDX) Up on FDA Nod to Xphozah for Hyperphosphatemia

by Zacks Equity Research

Ardelyx (ARDX) gets FDA approval for Xphozah to reduce serum phosphorus in adult patients with kidney disease on dialysis as an add-on therapy. The stock of the company climbs 13%.

Inovio Pharma (INO) Stock Surges 19% This Month: Here's Why

by Zacks Equity Research

Inovio Pharma (INO) rises 19% this month after the FDA issues positive feedback on data from a phase I/II study on a rare respiratory disease candidate, INO-3107, which can be used to file a BLA.

Nkarta (NKTX) Rallies 112% as FDA Clears IND for Lupus Drug

by Zacks Equity Research

Nkarta (NKTX) rallies 112% on FDA nod to begin the clinical development of its investigational candidate, NKX019, for the treatment of lupus nephritis.

Biomea (BMEA) Doses First Patient in Leukemia Study, Stock Up

by Zacks Equity Research

Biomea (BMEA) successfully doses the first patient in its phase I study of BMF-500 to treat adult patients with acute leukemia. The company's stock rises 6.7% on the news.

Adicet Bio, Inc. (ACET) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of -10.29% and 100%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Adicet Bio, Inc. (ACET) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of 2.70% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Arcturus Therapeutics (ARCT) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -69.86% and 39.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Legend Biotech Corporation Sponsored ADR (LEGN) Soars 19.6%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Legend Biotech Corporation Sponsored ADR (LEGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Akoya Biosciences (AKYA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Akoya (AKYA) delivered earnings and revenue surprises of -21.95% and 1.79%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Myriad Genetics (MYGN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Myriad (MYGN) delivered earnings and revenue surprises of 25% and 5.11%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Gilead's (GILD) Breast Cancer Drug Trodelvy Gets FDA Nod

by Zacks Equity Research

Gilead Sciences, Inc. (GILD) announces the FDA approval of their first-in-class, Trop-2 directed antibody-drug conjugate, Trodelvy, for the treatment of metastatic HR+/HER2- breast cancer in adult patients.

Karuna (KRTX) to Obtain Global Rights to Goldfinch's Candidates

by Zacks Equity Research

Karuna Therapeutics (KRTX) announces a definitive agreement with Goldfinch Bio to acquire global rights to the latter's lead clinical-stage candidate, GFB-887 and TRPC4/5 channel candidates.

Biogen (BIIB) & Eisai's Lecanemab Secures EMA's MAA Acceptance

by Zacks Equity Research

Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review.

Are Medical Stocks Lagging Adicet Bio (ACET) This Year?

by Zacks Equity Research

Here is how Adicet Bio, Inc. (ACET) and AlloVir, Inc. (ALVR) have performed compared to their sector so far this year.

Blueprint Medicines' (BPMC) Aykavit sNDA Gets FDA Priority Tag

by Zacks Equity Research

The FDA accepts and grants priority review to Blueprint Medicines' (BPMC) sNDA for the label expansion of Aykavit for indolent systemic mastocytosis.

Biomea (BMEA) Begins Dosing in Lung Cancer Study, Stock Up

by Zacks Equity Research

Biomea Fusion (BMEA) announces the successful dosing of the first patient in phase I/Ib study of BMF-219 in KRAS mutant solid tumors. Stocks rise 11.69% in response.

UnitedHealth's (UNH) UnitedHealthcare Unit to Aid Q4 Earnings?

by Zacks Equity Research

An increase in the number of people served in the commercial domestic business of UnitedHealth's (UNH) UnitedHealthcare segment is likely to boost fourth-quarter results.

UnitedHealth (UNH) to Post Q4 Earnings: What You Should Know

by Zacks Equity Research

UnitedHealth Group's (UNH) fourth-quarter results are likely to reflect growing premiums, products and higher expenses.